Sexually Transmitted Diseases Treatment Market 2019 with Key Players Merck, Pfizer, GlaxoSmithKline, Vertex Pharmaceuticals, Roche, Gilead Sciences

The number of products in pipeline for HIV treatment are high, which is expected to propel growth of the sexually transmitted disease treatment market. For instance, in 2017, GSK and ViiV Healthcare applied in European Medicines Agency (EMA) and US Food and Drug Administration (FDA), for regulatory affiliation for a single-tablet, two-drug regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used for treatment of HIV-1 infection. Moreover, other drug candidates in pipeline includes – PrEP, PRO140 with ibalizumab, BMS- 955176, which are expected to be launched in the forecast period. Moreover, governments are focusing on funding research and development programs, which is expected to aid in growth of the market. For instance, British Columbia Center for Disease Control sponsored doxycycline (drug) studies for indication of syphilis and other sexually transmitted infection, which is in early phase I clinical trial as of 2016.

Moreover, increasing governmental initiatives to spread awareness through organization of campaigns and free diagnostic camps is also expected to augment growth of the STDs treatment market. For instance, Centers for Disease Control and Prevention (CDC) launched Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies, or STD-AAPPS, in 2014. Moreover, in 2018, Thunder Bay Group—HIV / AIDS / hepatitis C education and support services provider— expanded the access of hepatitis C medicine for individuals with level 2 hepatitis C, after negotiating with the provinces and drug manufacturers.

However, growth of the sexually transmitted disease treatment market is expected to be restrained by low rate of screening for diseases and late diagnosis of the disease such as HIV.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2005

Sexually Transmitted Diseases Treatment market - Taxonomy

By Disease Type

Gonorrhea
Chlamydia
Syphilis
Herpes
Hepatitis (HBV)
Human Immunodeficiency Virus (HIV)
Other Indications
By Therapy Type

Anti-bacterial drugs
Anti-viral drugs
Anti-fungal drugs
By Route of Administration

Oral
Injectable
Topical

Sexually Transmitted Diseases Treatment market - Regional Analysis

Geographically, the sexually transmitted diseases treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant market, owing to rising government initiative for disease awareness and implementation of prenatal screening programs. However, Asia Pacific is expected to be fastest growing market for sexually transmitted diseases treatment, due to high incidence of sexually transmitted infections, owing to unprotected sexual practices in the region. For instance, according to Joint United Nations Programme on HIV and AIDS (UNAIDS), Asia Pacific had the second-highest number of people living with HIV in the world i.e. 5.1 million as of 2016, Moreover, China, India, and Indonesia accounts for three quarters of the total people living with HIV in Asia Pacific.

Sexually Transmitted Diseases Treatment market – Competitor

Major players in highly fragmented sexually transmitted diseases treatment market are Merck & Co. Inc., Pfizer INC, GlaxoSmithKline Plc, Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson and Bristol-Myers Squibb. Key players in sexually transmitted disease treatment market are focusing on adopting strategies such as mergers and collaborations for expanding their research for candidate drugs. For instance, in 2017, the drug Zoloflodacin entered into clinical trials, as a result of partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Moreover, in March 2018, Inovio Pharmaceuticals, Inc. entered into a deal with ApolloBio Corp., which have the exclusive rights for development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA immunotherapy product for pre-cancer indication.

Get Discount On This Report:
https://www.coherentmarketinsights.com/insight/request-discount/2005

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.